Karyopharm announces phase 3 boston study meets primary endpoint

Karyopharm announces phase 3 boston study meets primary endpoint with significant increase in progression-free survival in patients with multiple myeloma following one to three prior lines of therapy.karyopharm therapeutics inc - regulatory submission planned in 2q 2020; data to be submitted for presentation at upcoming medical meetings.karyopharm therapeutics inc - 47% increase in median pfs on svd versus vd.karyopharm therapeutics inc - boston study met its primary endpoint of a statistically significant increase in progression-free survival.karyopharm therapeutics inc - there were no new safety signals on svd arm and there was no imbalance in deaths between two arms in study.
KPTI Ratings Summary
KPTI Quant Ranking